What’s Happening at enGenome

enGenome and Genetic Alliance Partner to Expand Access to Advanced Genomic Interpretation for Rare Disease

Collaboration, initiated through Genetic Alliance laboratory partner, Dubai H…

Three Themes That Defined the First Half of 2026 for Genomics

By Ettore Rizzo, CEO, enGenome

ACMG SVC v4.0: A Significant Step Forward for Rare Disease Genomics

By Susanna Zucca, CSO, enGenome

How Oregon’s OHSU Knight Diagnostics Laboratories Supercharged Exome Workflows with eVai

The WGS Paradox: Why Clinical Genomics Is Advancing Faster Than Reimbursement Models

By Ettore Rizzo, CEO, enGenome

The Dark Genome and the Future of Predictive Genomics

By Susanna Zucca, CSO, enGenome

The Variant Interpretation Workforce Crisis: Genomics Is Scaling. The Experts Are Not.

By Ettore Rizzo, CEO, enGenome

enGenome at the AEGH Interdisciplinary Congress on Human Genetics 2026

The company will be present in Granada, Spain from April 15-17th at booth #3…

enGenome earns C5 Type 2 attestation for eVai cloud services in Germany

Strengthening data security and cloud compliance for clinical genomics

The $100 Genome Debate Misses the Real Challenge: Interpretation

By Ettore Rizzo, CEO, enGenome

AI-driven variant interpretation in focus at ACMG 2026

The company will welcome attendees at booth #2311

International day of women and girls in science

A conversation with Susanna Zucca, CSO & Co-founder of enGenome